Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 DiabetesKutz A, Kim D,Wexler D, Liu J, Schneeweiss S, Glynn R and Patorno EDiabetes Care 2023;46(11):2004–2014https://doi.org/10.2337/dc23-0671

The challenges of identifying and studying type 1 diabetes in adultsThomasJ, Jones ADiabetologia: December;2023;66: 2200 – 2212https://doi.org/10.1007/s00125-023-06004-4